Table 1.
Study design | Doses | Number of participants | Slope | No. of scenarios |
---|---|---|---|---|
SAD (4 periods/participants) | 0, 2.4, 4.0, 4.8 mg | 12, 24, 36, 48 | Zero, intermediate, high | 12 |
MAD (parallel) | 0, 1.2, 2.0, 2.4 mg twice daily | 12, 24, 36, 48 | Zero, intermediate, high | 12 |
SAD/MAD | As above | 12/36, 24/24, 36/12 | Zero, intermediate, high | 9 |
MAD, multiple‐ascending dose; SAD, single‐ascending dose.